Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-11-18
|
pubmed:abstractText |
Fluorine-18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) was used to image 38 patients with known or suspected malignant processes involving the abdomen or pelvis (including primary [n = 2] and secondary [n = 19] liver tumors, recurrent colon carcinoma [n = 1], lymphoma [n = 15], and cavernous hemangioma [n = 1]). PET results were compared with those from concurrent computed tomographic (CT) studies. Conspicuity of metastatic liver lesions on PET images often exceeded that of lesions on CT scans. Two well-differentiated primary liver tumors failed to show increased FDG uptake. Thirteen of the 15 patients with lymphoma had active disease, as determined with CT or clinical findings; 12 of 13 had increased FDG uptake on PET images. The false-negative result occurred in a patient with a low-grade lymphoma. The recurrent colorectal lesion was well demonstrated by PET, but further study is needed to determine whether it can be used to distinguish recurrent disease from radiation-induced changes. PET may be useful in determining the response to oncologic therapy, but PET does not reliably allow exclusion of low-grade lymphoma or well-differentiated hepatic lesions. Clinical correlation is always required in evaluating the significance of PET findings, as inflammatory conditions can also result in increased FDG uptake.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0271-5333
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1047-62
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8210589-Abdominal Neoplasms,
pubmed-meshheading:8210589-Carcinoma, Hepatocellular,
pubmed-meshheading:8210589-Colorectal Neoplasms,
pubmed-meshheading:8210589-Deoxyglucose,
pubmed-meshheading:8210589-Fluorodeoxyglucose F18,
pubmed-meshheading:8210589-Hemangioma, Cavernous,
pubmed-meshheading:8210589-Humans,
pubmed-meshheading:8210589-Liver Neoplasms,
pubmed-meshheading:8210589-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8210589-Pelvic Neoplasms,
pubmed-meshheading:8210589-Tomography, Emission-Computed
|
pubmed:year |
1993
|
pubmed:articleTitle |
Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.
|
pubmed:affiliation |
Department of Radiology, Massachusetts General Hospital, Boston 02114.
|
pubmed:publicationType |
Journal Article
|